Compare Stocks: LSTA, RNXT, EXOZ, and ATHE

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ATHE Alterity Therapeutics	$4.39 -1.6%	$4.73	$2.66 ▼ $5.89	$39.52M	0.27	12,150 shs	2,300 shs
EXOZ eXoZymes	$4.62 +0.4%	$7.18	$4.35 ▼ $18.40	$42.37M	2.93	9,182 shs	3,539 shs
LSTA Lisata Therapeutics	$1.14 +9.6%	$3.01	$0.99 ▼ $5.07	$9.47M	0.88	126,461 shs	162,499 shs
RNXT RenovoRx	$1.04 -1.9%	$0.91	$0.70 ▼ $1.45	$47.76M	0.99	222,000 shs	401,345 shs

10 Best Stocks to Own - Summer 2026

Enter your email address and we’ll send you MarketBeat’s list of ten stocks set to soar in Summer 2026, despite the threat of tariffs and what's happening in Iran. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ATHE Alterity Therapeutics	-1.57%	-3.41%	-18.10%	-2.88%	-15.74%
EXOZ eXoZymes	+0.43%	+5.00%	-45.52%	-53.33%	-53.52%
LSTA Lisata Therapeutics	+9.62%	-1.72%	-65.77%	-65.03%	-55.64%
RNXT RenovoRx	-1.89%	+14.63%	+13.03%	+16.87%	-14.05%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ATHE Alterity Therapeutics	$4.39 -1.6%	$4.73	$2.66 ▼ $5.89	$39.52M	0.27	12,150 shs	2,300 shs
EXOZ eXoZymes	$4.62 +0.4%	$7.18	$4.35 ▼ $18.40	$42.37M	2.93	9,182 shs	3,539 shs
LSTA Lisata Therapeutics	$1.14 +9.6%	$3.01	$0.99 ▼ $5.07	$9.47M	0.88	126,461 shs	162,499 shs
RNXT RenovoRx	$1.04 -1.9%	$0.91	$0.70 ▼ $1.45	$47.76M	0.99	222,000 shs	401,345 shs

10 Best Stocks to Own - Summer 2026

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ATHE Alterity Therapeutics	-1.57%	-3.41%	-18.10%	-2.88%	-15.74%
EXOZ eXoZymes	+0.43%	+5.00%	-45.52%	-53.33%	-53.52%
LSTA Lisata Therapeutics	+9.62%	-1.72%	-65.77%	-65.03%	-55.64%
RNXT RenovoRx	-1.89%	+14.63%	+13.03%	+16.87%	-14.05%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ATHE Alterity Therapeutics	2.40	Hold	$13.00	196.13% Upside
EXOZ eXoZymes	1.00	Sell	N/A	N/A
LSTA Lisata Therapeutics	1.67	Reduce	$15.00	1,215.79% Upside
RNXT RenovoRx	2.75	Moderate Buy	$8.50	717.31% Upside

Current Analyst Ratings Breakdown

Latest LSTA, RNXT, EXOZ, and ATHE Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/31/2026	LSTA Lisata Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
7/17/2026	ATHE Alterity Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (E+)
7/17/2026	LSTA Lisata Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
7/17/2026	RNXT RenovoRx	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
6/30/2026	ATHE Alterity Therapeutics	JonesTrading Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy	$16.00
6/29/2026	RNXT RenovoRx	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
6/17/2026	ATHE Alterity Therapeutics	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Hold
6/16/2026	ATHE Alterity Therapeutics	LADENBURG THALM/SH SH Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy	$10.00
6/8/2026	RNXT RenovoRx	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
6/1/2026	RNXT RenovoRx	Ascendiant Capital Markets Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$13.50 ➝ $14.00
5/29/2026	EXOZ eXoZymes	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (E+)

(Data available from 8/5/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ATHE Alterity Therapeutics	N/A	N/A	N/A	N/A	$3.10 per share	N/A
EXOZ eXoZymes	$70K	607.86	N/A	N/A	$0.40 per share	11.55
LSTA Lisata Therapeutics	$170K	61.09	N/A	N/A	$1.66 per share	0.69
RNXT RenovoRx	$1.12M	41.83	N/A	N/A	$0.15 per share	6.93

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ATHE Alterity Therapeutics	-$7.87M	N/A	N/A	N/A	N/A	N/A	N/A	N/A	8/28/2026 (Estimated)
EXOZ eXoZymes	-$9.16M	-$1.14	N/A	N/A	N/A	N/A	-220.63%	-141.26%	N/A
LSTA Lisata Therapeutics	-$16.59M	-$1.86	N/A	N/A	N/A	N/A	-103.54%	-83.08%	8/6/2026 (Estimated)
RNXT RenovoRx	-$11.17M	-$0.33	N/A	N/A	N/A	-823.98%	-135.03%	-101.92%	8/12/2026 (Estimated)

Latest LSTA, RNXT, EXOZ, and ATHE Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/28/2026	Q4 2026 TU	ATHE Alterity Therapeutics	-$0.1455	N/A	N/A	N/A	$2.48 million	N/A
8/12/2026	Q2 2026	RNXT RenovoRx	-$0.08	N/A	N/A	N/A	$0.70 million	N/A
5/14/2026	Q1 2026	EXOZ eXoZymes	N/A	-$0.28	N/A	-$0.28	N/A	N/A
5/14/2026	Q1 2026	RNXT RenovoRx	-$0.08	-$0.08	N/A	-$0.09	$0.47 million	$0.56 million
5/11/2026	Q1 2026	LSTA Lisata Therapeutics	N/A	-$0.50	N/A	-$0.50	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
ATHE Alterity Therapeutics	N/A	N/A	N/A	N/A	N/A
EXOZ eXoZymes	N/A	N/A	N/A	N/A	N/A
LSTA Lisata Therapeutics	N/A	N/A	N/A	N/A	N/A
RNXT RenovoRx	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ATHE Alterity Therapeutics	N/A	21.97	N/A
EXOZ eXoZymes	0.03	1.32	1.32
LSTA Lisata Therapeutics	N/A	4.23	4.23
RNXT RenovoRx	N/A	7.15	6.95

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ATHE Alterity Therapeutics	2.14%
EXOZ eXoZymes	N/A
LSTA Lisata Therapeutics	8.94%
RNXT RenovoRx	3.10%

Insider Ownership

Company	Insider Ownership
ATHE Alterity Therapeutics	38.80%
EXOZ eXoZymes	72.41%
LSTA Lisata Therapeutics	9.10%
RNXT RenovoRx	9.40%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ATHE Alterity Therapeutics	10	8.87 million	5.43 million	Not Optionable
EXOZ eXoZymes	29	9.21 million	2.54 million	N/A
LSTA Lisata Therapeutics	30	9.11 million	8.28 million	Not Optionable
RNXT RenovoRx	6	45.05 million	40.82 million	Not Optionable

LSTA, RNXT, EXOZ, and ATHE Headlines

Recent News About These Companies

RenovoRx to Highlight TAMP™ Platform at JonesTrading Virtual Key Opinion Leader Webinar on the Evolving Pancreatic Cancer Landscape, August 13th

August 4 at 8:30 AM | globenewswire.com

RenovoRx (RNXT) Stock Forecast & Price Target

August 2 at 11:23 PM | investing.com

RenovoRx to Host Second Quarter 2026 Financial Results and Business Highlights Conference Call on August 12th at 4:30 p.m. ET

July 29, 2026 | globenewswire.com

RenovoRx Stock Short Interest Report | NASDAQ:RNXT | Benzinga

July 7, 2026 | benzinga.com

RenovoRx Stockholders Approve Directors and Equity Plan

June 30, 2026 | tipranks.com

RenovoRx, Inc. (RNXT) Presents at IAccess Alpha Virtual Best Ideas Summer Investment Conference 2026 Transcript

June 23, 2026 | seekingalpha.com

RenovoRx Highlights Peer-Reviewed Publication Supporting Intra-Arterial Gemcitabine Delivery Via TAMP™ in Locally Advanced Pancreatic Cancer

June 11, 2026 | globenewswire.com

Ascendiant Remains a Buy on RenovoRx (RNXT)

June 5, 2026 | theglobeandmail.com

RenovoRx CEO, Shaun Bagai, to Present at the iAccess Alpha Virtual Best Ideas Summer Investment Conference 2026 on June 23rd

June 4, 2026 | globenewswire.com

RenovoRx, Inc.: RenovoRx Announces FDA Orphan Drug Designation Granted: Oxaliplatin for the Treatment of Pancreatic Cancer

May 28, 2026 | finanznachrichten.de

RenovoRx Announces FDA Orphan Drug Designation Granted: Oxaliplatin for the Treatment of Pancreatic Cancer

May 28, 2026 | globenewswire.com

RenovoRx Announces Promising Pharmacokinetic Data Using the TAMP™ Platform Presented at the 2026 ASCO Annual Meeting

May 26, 2026 | globenewswire.com

Mark Voll Buys 25,000 Shares of RenovoRx (NASDAQ:RNXT) Stock

May 22, 2026 | insidertrades.com

RenovoRx (RNXT) Q1 2026 Earnings Transcript

May 19, 2026 | fool.com

RenovoRx to Present at the Alliance Global Partners Virtual Annual Healthcare Company Showcase on May 20th

May 19, 2026 | globenewswire.com

Shaun Bagai, CEO of Renovorx, buys $0 of RNXT stock

May 18, 2026 | investing.com

RenovoRx Inc (RNXT) Q1 2026 Earnings Call Highlights: Record Revenue and Strategic Expansion

May 15, 2026 | finance.yahoo.com

RenovoRx, Inc. (RNXT) Reports Q1 Loss, Tops Revenue Estimates

May 14, 2026 | zacks.com

RenovoRx Reports Record First Quarter 2026: Increasing Revenue by 136% Quarter-over-Quarter

May 14, 2026 | finance.yahoo.com

RenovoRx Inc (RNXT) Q1 2026 Earnings Report Preview: What To Expect

May 14, 2026 | finance.yahoo.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

LSTA, RNXT, EXOZ, and ATHE Company Descriptions

Alterity Therapeutics NASDAQ:ATHE

$4.39 -0.07 (-1.57%)

Closing price 08/4/2026 03:59 PM Eastern

Extended Trading

$4.47 +0.08 (+1.82%)

As of 08/4/2026 07:34 PM Eastern

Alterity Therapeutics Limited engages in the research and development of therapeutic drugs to treat Alzheimer's disease, Huntington disease, Parkinson's disease, and other neurological disorders in Australia. The company's lead drug candidate is ATH434 that is in Phase I clinical trial for the treatment of Parkinson's disease. It is also developing ATH434-201, which is in Phase II clinical trial to treat multiple system atrophy early stage; ATH434-202 that is in Phase II clinical trial to treat multiple system atrophy advance; and PBT2 that has completed Phase 2a clinical trial to treat Alzheimer's disease. The company was formerly known as Prana Biotechnology Limited and changed its name to Alterity Therapeutics Limited in April 2019. Alterity Therapeutics Limited was incorporated in 1997 and is headquartered in Melbourne, Australia.

eXoZymes NASDAQ:EXOZ

$4.62 +0.02 (+0.43%)

Closing price 08/4/2026 04:00 PM Eastern

Extended Trading

$4.60 -0.02 (-0.43%)

As of 08/4/2026 04:45 PM Eastern

eXoZymes, Inc. is a development stage synthetic biochemical company. Its synthetic biology platform would enable the scalable exploration of many molecules and properties found in nature. The company was founded by Tyler Korman and Paul Opgenorth in April 2019 and is headquartered in Monrovia, NV.

Lisata Therapeutics NASDAQ:LSTA

$1.14 +0.10 (+9.62%)

Closing price 08/4/2026 04:00 PM Eastern

Extended Trading

$1.18 +0.04 (+3.60%)

As of 04:00 AM Eastern

Lisata Therapeutics, Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of innovative therapies for the treatment of solid tumors and other diseases. Its product candidates include LSTA1, which is in Phase 2a and 2b clinical studies for the treatment of solid tumor, including metastatic pancreatic ductal adenocarcinoma (mPDAC), in combination with a range of anti-cancer regimens; XOWNA that is in Phase IIa clinical trial for the treatment of coronary microvascular dysfunction; and CD34+ cell therapy for the treatment of chronic kidney disease. Lisata Therapeutics, Inc. was incorporated in 1980 and is headquartered in Basking Ridge, New Jersey.

RenovoRx NASDAQ:RNXT

$1.04 -0.02 (-1.89%)

Closing price 08/4/2026 04:00 PM Eastern

Extended Trading

$1.02 -0.02 (-1.44%)

As of 08:21 AM Eastern

RenovoRx, Inc., a clinical-stage biopharmaceutical company, focuses on developing proprietary targeted combination therapies to improve therapeutic outcomes for cancer patients undergoing treatment. Its lead product candidate is RenovoGem, an oncology drug-device combination product, consisting of intra-arterial gemcitabine and RenovoCath that is in Phase III clinical trials for the locally advanced pancreatic cancer. The company has a research collaboration with Imugene Limited to deliver oncolytic virus therapy for the treatment of difficult-to-access tumors. RenovoRx, Inc. was founded in 2009 and is headquartered in Los Altos, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest LSTA, RNXT, EXOZ, and ATHE Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest LSTA, RNXT, EXOZ, and ATHE Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

LSTA, RNXT, EXOZ, and ATHE Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

LSTA, RNXT, EXOZ, and ATHE Company Descriptions

Alterity Therapeutics NASDAQ:ATHE

eXoZymes NASDAQ:EXOZ

Lisata Therapeutics NASDAQ:LSTA

RenovoRx NASDAQ:RNXT

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest LSTA, RNXT, EXOZ, and ATHE Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest LSTA, RNXT, EXOZ, and ATHE Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

LSTA, RNXT, EXOZ, and ATHE Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

LSTA, RNXT, EXOZ, and ATHE Company Descriptions

Alterity Therapeutics NASDAQ:ATHE

eXoZymes NASDAQ:EXOZ

Lisata Therapeutics NASDAQ:LSTA

RenovoRx NASDAQ:RNXT

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools